Delivery Order SPE2DB24D2011-SPE2DB25FBRJB
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,529.88 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This firm fixed-price delivery order, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a competitively awarded contract with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,060.55 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This firm fixed-price, competitively awarded delivery order was issued on September 15, 2025, with an ultimate completion date of September 16, 2025. The contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units, valued at $2,947.88. This competitive award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, utilizes firm fixed pricing under a non-set-aside procurement. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary...
- The Defense Logistics Agency awarded a $1,871.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $1,550.46 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Multaq (dronedarone) is an antiarrhythmic medication used in the...
- The Defense Logistics Agency awarded a delivery order valued at $3,059.76 to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a 60-count package. This non-set-aside, firm fixed-price delivery order was awarded on August 6, 2025, with an ultimate completion date of August 7, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. Multaq is an antiarrhythmic medication used to treat atrial fibrillation, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $6,661.37 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This firm fixed price, competitively awarded contract—with no set-aside designation—was executed on July 22, 2025, with an ultimate completion date of July 23, 2025. The award reflects a rapid fulfillment timeline typical of delivery orders placed against existing contract vehicles. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units, valued at $4,506.52. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $18,897.41 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on September 11, 2025, with completion scheduled for September 12, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,487.82 to AmerisourceBergen Drug Corp for 60 tablets of Multaq 400 mg on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procedures. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly...
- SPE2DB24D2011Indefinite Delivery Contract
- SPE2DB24D2011-SPE2DB25FBRJBDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,078.41 to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Multaq 400 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a competitive award with no set-aside designation and is performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, fulfills this order under its existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated as SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. Multaq (dronedarone) is an antiarrhythmic medication used to reduce the risk of cardiovascular events in patients with paroxysmal or persistent atrial fibrillation. This delivery order exemplifies the type of pharmaceutical product deliveries that AmerisourceBergen routinely supplies through its comprehensive DLA contract vehicle, which encompasses brand-name and generic drugs, vaccines, and specialized medical supplies across multiple therapeutic domains to support military and veteran healthcare systems. The company's federal contracting history demonstrates consistent capability to meet competitive procurement requirements and deliver pharmaceuticals with firm fixed pricing across a diverse range of transaction values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.1k | 7/21/25 |